Tissue factor and cancer

Pathophysiology of Haemostasis and Thrombosis

Volumn 36, Issue 3-4, 2008, Pages 160-176

  Milsom, Chloe ^a   Rak, Janusz ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MONTREAL CHILDREN S HOSPITAL   (Canada)

Author keywords

Angiogenesis; Anti tissue factor therapy; Cancer; Coagulation; Oncogenes; Tissue factor

Indexed keywords

ANGIOGENESIS INHIBITOR; CANERTINIB; CETUXIMAB; HIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; RETINOIC ACID; THROMBOPLASTIN; ANTINEOPLASTIC AGENT; BLOOD CLOTTING FACTOR; TUMOR PROTEIN;

ANGIOGENESIS; BLEEDING; BLOOD CLOTTING DISORDER; CANCER PATIENT; CELL HETEROGENEITY; DISEASE COURSE; DRUG TARGETING; HUMAN; METASTASIS; NEOPLASM; PRIORITY JOURNAL; REVIEW; SAFETY; SIGNAL TRANSDUCTION; TUMOR GROWTH; ANIMAL; ANTIBODY SPECIFICITY; BIOLOGICAL MODEL; BLOOD; CELL TRANSFORMATION; DRUG DELIVERY SYSTEM; GENETICS; HEMOSTASIS; MEMBRANE MICROPARTICLE; MOUSE; MOUSE MUTANT; NEOVASCULARIZATION (PATHOLOGY); ONCOGENE; PATHOPHYSIOLOGY; PHYSIOLOGY; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOPHILIA; TUMOR SUPPRESSOR GENE; ULTRASTRUCTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD COAGULATION FACTORS; BLOOD PLATELETS; CELL TRANSFORMATION, NEOPLASTIC; CELL-DERIVED MICROPARTICLES; DRUG DELIVERY SYSTEMS; GENES, TUMOR SUPPRESSOR; HEMOSTASIS; HUMANS; MICE; MICE, KNOCKOUT; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; ONCOGENES; ORGAN SPECIFICITY; PLATELET ACTIVATION; THROMBOPHILIA; THROMBOPLASTIN;

EID: 61449255591     PISSN: 14248832     EISSN: None     Source Type: Journal    
DOI: 10.1159/000175154     Document Type: Review

References (279)

1. Mackman N, Morrissey JH, Fowler B, Edgington TS: Complete sequence of the human tissue factor gene, a highly regulated cellular receptor that initiates the coagulation protease cascade. Biochemistry 1989;28:1755-1762.
2. Chen J, Bierhaus A, Schiekofer S, Andrassy M, Chen B, Stern DM, Nawroth PP: Tissue factor-αreceptor involved in the control of cellular properties, including angiogenesis. Thromb Haemost 2001;86: 334-345.
3. Morrissey JH: Tissue factor: an enzyme co-factor and a true receptor. Thromb Haemost 2001;86:66-74.
4. Fernandez PM, Rickles FR: Tissue factor and angiogenesis in cancer. Curr Opin Hematol 2002;9: 401-406.
5. Giesen PL, Rauch U, Bohrmann B, Kling D, Roque M, Fallon JT, Badimon JJ, Himber J, Riederer MA, Nemerson Y: Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA 1999;96:2311-2315.
6. Mackman N: Tissue-specific hemostasis: role of tissue factor. J Thromb Haemost 2007.
7. Butenas S, Orfeo T, Brummel-Ziedins KE, Mann KG: Tissue factor in thrombosis and hemorrhage. Surgery 2007;142:S2-S14.
8. Coughlin SR: Thrombin signalling and protease-activated receptors. Nature 2000;407: 258-264.
9. Pawlinski R, Pedersen B, Erlich J, Mackman N: Role of tissue factor in haemostasis, thrombosis, angiogenesis and inflammation: lessons from low tissue factor mice. Thromb Haemost 2004;92: 444-450.
10. Ossovskaya VS, Bunnett NW: Protease-activated receptors: contribution to physiology and disease. Physiol Rev 2004;84: 579-621.
11. Belting M, Ahamed J, Ruf W: Signaling of the tissue factor coagulation pathway in angiogenesis and cancer. Arterioscler Thromb Vasc Biol 2005;25:1545-1550.
12. O'Brien PJ, Prevost N, Molino M, Hollinger MK, Woolkalis MJ, Woulfe DS, Brass LF: Thrombin responses in human endothelial cells. Contributions from receptors other than PAR1 include the transactivation of PAR2 by thrombin-cleaved PAR1. J Biol Chem 2000;275:13502-13509.
13. Ruf W: Tissue factor-dependent signaling in tumor biology. Pathophysiol Haemost Thromb 2003;33(suppl 1):28-30.
14. Nierodzik ML, Karpatkin S: Thrombin induces tumor growth, metastasis, and an-giogenesis: evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell 2006;10:355-362.
15. Pawlinski R, Tencati M, Holscher T, Pedersen B, Voet T, Tilley RE, Marynen P, Mackman N: Role of cardiac myocyte tissue factor in heart hemostasis. J Thromb Haemost 2007;5: 16 9 3-17 0 0 .
16. Ott I, Fischer EG, Miyagi Y, Mueller BM, Ruf W: A role for tissue factor in cell adhesion and migration mediated by interaction with actin-binding protein 280. J Cell Biol 1998;14 0 : 1241-1253.
17. Nakagawa K, Zhang Y, Tsuji H, Yoshizumi M, Kasahara T, Nishimura H, Nawroth PP, Nakagawa M: The angiogenic effect of tissue factor on tumors and wounds. Semin Thromb Hemost 1998;24:207-210.
18. Abe K, Shoji M, Chen J, Bierhaus A, Danave I, Micko C, Casper K, Dillehay DL, Nawroth PP, Rickles FR: Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci USA 1999;96: 8663-8668.
19. Pendurthi UR, Allen KE, Ezban M, Rao LV: Factor VIIa and thrombin induce the expression of Cyr61 and connective tissue growth factor, extracellular matrix signaling proteins that could act as possible downstream mediators in factor VIIa ! tissue factor-induced signal transduction. J Biol Chem 2000;275: 14 63 2-14 6 41.
20. Bromberg ME, Cappello M: Cancer and blood coagulation: molecular aspects. Cancer J Sci Am 1999;5: 132-138 .
21. Camerer E, Gjernes E, Wiiger M, Pringle S, Prydz H: Binding of factor VIIa to tissue factor on keratinocytes induces gene expression. J Biol Chem 2000;275: 6580-6585.
22. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Van-denhoeck A, Harpal K, Eberhardt C, De-clercq C, Pawling J, Moons L, Collen D, Risau W, Nagy A: Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996;380:435-439.
23. Bugge TH, Xiao Q, Kombrinck KW, Flick MJ, Holmback K, Danton MJ, Colbert MC, Witte DP, Fujikawa K, Davie EW, Degen JL: Fatal embryonic bleeding events in mice lacking tissue factor, the cell-associated initiator of blood coagulation. Proc Natl Acad Sci USA 1996;93:6258-6263.
24. Toomey JR, Kratzer KE, Lasky NM, Stanton JJ, Broze GJ Jr: Targeted disruption of the murine tissue factor gene results in embryonic lethality. Blood 1996;88: 1583-1587.
25. Belting M, Dorrell MI, Sandgren S, Aguilar E, Ahamed J, Dorfleutner A, Carmeliet P, Mueller BM, Friedlander M, Ruf W: Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med 2004;10: 502-509.
26. Parry GC, Mackman N: Mouse embryogenesis requires the tissue factor extracellular domain but not the cytoplasmic domain. J Clin Invest 2000;105:1547-1554.
27. Drake TA, Ruf W, Morrissey JH, Edging ton TS: Functional tissue factor is entirely cell surface expressed on lipopolysaccharide-stimulated human blood monocytes and a constitutively tissue factor-producing neoplastic cell line. J Cell Biol 1989;109:389-395.
28. Fleck RA, Rao LV, Rapaport SI, Varki N: Localization of human tissue factor antigen by immunostaining with monospecific, polyclonal anti-human tissue factor antibody. Thromb Res 1990;59:421-437.
29. Mackman N, Sawdey MS, Keeton MR, Loskutoff DJ: Murine tissue factor gene expression in vivo. Tissue and cell specificity and regulation by lipopolysaccharide. Am J Pathol 1993;14 3 : 76- 8 4.
30. Mackman N: Tissue-specific hemostasis in mice. Arterioscler Thromb Vasc Biol 2005;25:2273-2281.
31. Falanga A: Thrombophilia in cancer. Semin Thromb Hemost 2005;31:104-110.
32. Rickles FR: Mechanisms of cancer-induced thrombosis in cancer. Pathophysiol Haemost Thromb 2006;35:103-110.
33. Mackman N, Tilley RE, Key NS: Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol 2007;27: 16 8 7-16 9 3 .
34. Monroe DM, Key NS: The tissue factor-factor VIIa complex: procoagulant activity, regulation, and multitasking. J Thromb Haemost 2007;5: 1097-1105.
35. Egorina EM, Sovershaev MA, Osterud B: Regulation of tissue factor procoagulant activity by post-translational modifications. Thromb Res 2008;122:831-837.
36. Mackman N: Regulation of the tissue factor gene. Thromb Haemost 1997;78: 74 7-7 5 4 .
37. Ruf W: Emerging roles of tissue factor in viral hemorrhagic fever. Trends Immunol 2004;25:461-464.
38. Carson SD, Bromberg ME: Tissue factor encryption/de-encryption is not altered in the absence of the cytoplasmic domain. Thromb Haemost 2000;84: 657- 6 63.
39. Wolberg AS, Kon RH, Monroe DM, Ezban M, Roberts HR, Hoffman M: Deencryption of cellular tissue factor is independent of its cytoplasmic domain. Biochem Biophys Res Commun 2000;272: 332-336 .
40. Bogdanov VY, Balasubramanian V, Hathcock J, Vele O, Lieb M, Nemerson Y: A lternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med 2003;9:458-462.
41. Chand HS, Ness SA, Kisiel W: Identification of a novel human tissue factor splice variant that is upregulated in tumor cells. Int J Cancer 2006;118: 1713-1720.
42. Haas SL, Jesnowski R, Steiner M, Hummel F, Ringel J, Burstein C, Nizze H, Liebe S, Lohr JM: Expression of tissue factor in pancreatic adenocarcinoma is associated with activation of coagulation. World J Gastroenterol 2006;12:4843-4849.
43. Hobbs JE, Zakarija A, Cundiff DL, Doll JA, Hymen E, Cornwell M, Crawford SE, Liu N, Signaevsky M, Soff GA: Alternatively spliced human tissue factor promotes tumor growth and angiogenesis in a pancreatic cancer tumor model. Thromb Res 2007;120(suppl 2): S13-S21.
44. Butenas S, Mann KG: Active tissue factor in blood? Nat Med 2004;10:1155-1156.
45. Dvorak HF, Quay SC, Orenstein NS, Dvorak AM, Hahn P, Bitzer AM, Carvalho AC: Tumor shedding and coagulation. Science 1981;212:923-924.
46. Yu JL, Rak JW: Shedding of tissue factor (TF)-containing microparticles rather than alternatively spliced TF is the main source of TF activity released from human cancer cells. J Thromb Haemost 2004;2: 2065-2067.
47. Del Conde I, Shrimpton CN, Thiagarajan P, Lopez JA: Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood 2005;106:1604-1611.
48. Babiker AA, Hamad OA, Sanchez J, Ronquist G, Nilsson B, Ekdahl KN: Prothrombotic effect of prostasomes of metastatic cell and seminal origin. Prostate 2007;67:378-388.
49. Langer F, Chun FK, Amirkhosravi A, Friedrich M, Leuenroth S, Eifrig B, Bokemeyer C, Francis JL: Plasma tissue factor antigen in localized prostate cancer: distribution, clinical significance and correlation with haemostatic activation markers. Thromb Haemost 2007;97:464-470.
50. Rauch U, Antoniak S, Boots M, Schulze K, Goldin-Lang P, Stein H, Schultheiss HP, Coupland SE: Association of tissue-factor upregulation in squamous-cell carcinoma of the lung with increased tissue factor in circulating blood. Lancet Oncol 2005;6:254.
51. Hron G, Kollars M, Weber H, Sagaster V, Quehenberger P, Eichinger S, Kyrle PA, Weltermann A: Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost 2007;97: 119-123.
52. Tesselaar ME, Romijn FP, Van DL, I, Prins FA, Bertina RM, Osanto S: Microparticle-as-sociated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost 2007;5:520-527.
53. Del Conde I, Bharwani LD, Dietzen DJ, Pen-durthi U, Thiagarajan P, Lopez JA: Microvesicle-associated tissue factor and Trousseau's syndrome. J Thromb Haemost 2007;5: 70-74.
54. Tilley RE, Holscher T, Belani R, Nieva J, Mackman N: Tissue factor activity is increased in a combined platelet and microparticle sample from cancer patients. Thromb Res 2008.
55. Pilzer D, Gasser O, Moskovich O, Schifferli JA, Fishelson Z: Emission of membrane vesicles: roles in complement resistance, immunity and cancer. Springer Semin Immuno-pathol 2005;27: 375-387.
56. Olas B, Lundell K, Holmsen H, Fukami MH: Biochemical properties of platelet microparticle membranes formed during exocytosis resemble organelles more than plasma membrane. FEBS Lett 2002;525 : 29-32 .
57. Yu JL, May L, Lhotak V, Shahrzad S, Shirasawa S, Weitz JI, Coomber BL, Mackman N, Rak JW: Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and an-giogenesis. Blood 2005;105:1734-1741.
58. Barry OP, FitzGerald GA: Mechanisms of cellular activation by platelet microparticles. Thromb Haemost 1999;82: 794-80 0.
59. Mallat Z, Benamer H, Hugel B, Benessiano J, Steg PG, Freyssinet JM, Tedgui A: Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 2000;101: 841-843.
60. Diamant M, Tushuizen ME, Sturk A, Nieuw-land R: Cellular microparticles: new players in the field of vascular disease? Eur J Clin Invest 2004;34:392-401.
61. Ma llat Z , Hugel B, Oha n J, Lesèche G, Freyssinet JM, Tedgui A: Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. Circulation 1999;99:348-353.
62. Morel O, Toti F, Hugel B, Bakouboula B, Camoin-Jau L, Dignat-George F, Freyssinet JM: Procoagulant microparticles: disrupting the vascular homeostasis equation? Arterioscler Thromb Vasc Biol 2006;26:2594-2604.
63. Nieuwland R, Berckmans RJ, McGregor S, Boing AN, Romijn FP, Westendor p RG, Hack CE, Sturk A: Cellular origin and procoagulant properties of microparticles in meningococca l sepsis. Blood 20 00;95: 930-935.
64. Joop K, Berckmans RJ, Nieuwland R, Berkhout J, Romijn FP, Hack CE, Sturk A: Microparticles from patients with multiple organ dysfunction syndrome and sepsis support coagulation through multiple mechanisms. Thromb Haemost 2001;85:810-820 .
65. Chamouard P, Desprez D, Hugel B, Kunzelmann C, Gidon-Jeangirard C, Lessard M, Baumann R, Freyssinet JM, Grunebaum L: Circulating cell-derived microparticles in Crohn's disease. Dig Dis Sci 2005;50:574-580.
66. Amengual O, Atsumi T, Khamashta MA, Hughes GR: The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 1998;79:276-281.
67. Pereira J, Alfaro G, Goycoolea M, Quiroga T, Ocqueteau M, Massardo L, Perez C, Saez C, Panes O, Matus V, Mezzano D: Circulating platelet-derived microparticles in systemic lupus erythematosus. Association with increased thrombin generation and procoagu-lant state. Thromb Haemost 20 06;95:94-99.
68. Key NS, Slungaard A, Dandelet L, Nelson SC, Moertel C, Styles LA, Kuypers FA, Bach RR: Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood 1998;91:4216-4223.
69. Shet AS, Aras O, Gupta K, Hass MJ, Rausch DJ, Saba N, Koopmeiners L, Key NS, Hebbel RP: Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood 2003;102:2678-2683.
70. Diamant M, Nieuwland R, Pablo RF, Sturk A, Smit JW, Radder JK: Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus. Circulation 2002;106:2442-2447.
71. Sabatier F, Darmon P, Hugel B, Combes V, Sanmarco M, Velut JG, Arnoux D, Charpiot P, Freyssinet JM, Oliver C, Sa mpol J, Dignat-George F: Type 1 and type 2 diabetic patients display different patterns of cellular microparticles. Diabetes 2002;51:2840-2845.
72. D'Addario G, Rauch D, Stupp R, Pless M, Stahel R, Mach N, Jost L, Widmer L, Tapia C, BihlM, Mayer M, Ribi K, L erch S , Bubendor f L, Betticher DC: Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK Protocol 19/03. Ann Oncol 2008;19:739-745.
73. Trousseau A: Phlegmasia alba dolens;in Trousseau A (ed): Clinique médicinale de l'Hôtel-Dieu de Paris. Paris, J.-B. Baillière &Fils, 1865, pp 645-712.
74. Levine MN, Lee AY, Kakkar AK: From Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer. J Thromb Haemost 2003;1:1456-1463.
75. Buller HR, van Doormaal FF, van Sluis GL, Kamphuisen PW: Cancer and thrombosis: from molecular mechanisms to clinical presentations. J Thromb Haemost 2007;5(suppl 1):246-254.
76. Rickles FR, Patierno S, Fernandez PM: Tissue factor, thrombin, and cancer. Chest 2003;124:58S-68S.
77. Furie B, Furie BC: Cancer-associated thrombosis. Blood Cells Mol Dis 2006;36:177-181.
78. Petralia GA, Lemoine NR, Kakkar AK: Mechanisms of disease: the impact of antithrombotic therapy in cancer patients. Nat Clin Pract Oncol 2005;2:356-363.
79. Gordon SG, Mielicki WP: Cancer procoagu-lant: a factor X activator, tumor marker and growth factor from malignant tissue. Blood Coagul Fibrinolysis 1997;8:73-86.
80. Erman M, Abali H, Oran B, Haznedaroglu IC, Canpinar H, Kirazli S, Celik I: Tamoxi-fen-induced tissue factor pathway inhibitor reduction: a clue for an acquired thrombo-philic state? Ann Oncol 2004;15:1622-1626.
81. Sato N, Parker AR, Fukushima N, Miyagi Y, Iacobuzio-Donahue CA, Eshleman JR, Goggins M: Epigenetic inactivation of TFPI-2 as a common mechanism associated with growth and invasion of pancreatic ductalad-enocarcinoma. Oncogene 2005;24:850-858.
82. Rollin J, Iochmann S, Blechet C, Hube F, Regina S, Guyetant S, Lemarie E, Reverdiau P, Gruel Y: Expression and methylation status of tissue factor pathway inhibitor-2 gene in non-small-cell lung cancer. Br J Cancer 2005;92:775-783.
83. Ma L, Francia G, Viloria-Petit A, Hicklin DJ, du MJ, Rak J, Kerbel RS: In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy. Cancer Res 2005;65:5365-5373.
84. Boccaccio C, Sabatino G, Medico E, Girolami F, Follenzi A, Reato G, Sottile A, Naldini L, Comoglio PM: The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature 2005;434:396-400.
85. Woodley-Cook J, Shin LY, Swystun L, Caruso S, Beaudin S, Liaw PC: Effects of the che-motherapeutic agent doxorubicin on the protein C anticoagulant pathway. Mol Cancer Ther 2006;5:3303-3311.
86. Rak J, Yu JL, Luyendyk J, Mackman N: Oncogenes, Trousseau syndrome, and cancer-related changes in the coagulome of mice and humans. Cancer Res 2006;66:10643-10646.
87. Dvorak HF, Van DL, Bitzer AM, Dvorak AM, Anderson D, Harvey VS, Bach R, Davis GL, DeWolf W, Carvalho AC: Procoagulant activity associated with plasma membrane vesicles shed by cultured tumor cells. Cancer Res 1983;43:4434-4442.
88. Yu JL, May L, Klement P, Weitz JI, Rak J: On-cogenes as regulators of tissue factor expression in cancer: implications for tumor angiogenesis and anti-cancer therapy. Semin Thromb Hemost 2004;30:21-30.
89. Tallman MS, Lefebvre P, Baine RM, Shoji M, Cohen I, Green D, Kwaan HC, Paietta E, Rickles FR: Effects of all-trans-retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibri-nolysis in patients with acute promyelocytic leukemia. J Thromb Haemost 2004;2:1341-1350.
90. Rong Y, Post DE, Pieper RO, Durden DL, Van Meir EG, Brat DJ: PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res 2005;65:1406-1413.
91. Sato T, Tsujino I, Ikeda D, Ieko M, Nishimura M: Trousseau's syndrome associated with tissue factor produced by pulmonary adenocarcinoma. Thorax 2006;61:1009-1010.
92. Kakkar AK, Lemoine NR, Scully MF, Tebbutt S, Williamson RC: Tissue factor expression correlates with histological grade in human pancreatic cancer. Br J Surg 1995;82: 1101-110 4.
93. Ueno T, Toi M, Koike M, Nakamura S, Tominaga T: Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration. Br J Cancer 2000;83:164-170.
94. Milsom C, Yu J, May L, Meehan B, Magnus N, Al Nedawi K, Luyendyk J, Weitz J, Kle ment P, Broze G, Mackman N, Rak J: The role of tu-mor-and host-related tissue factor pools in on-cogene-driven tumor progression. Thromb Res 2007;120(suppl 2):S82-S91.
95. Wojtukiewicz MZ, Sierko E, Klement P, Rak J: The hemostatic system and angiogenesis in malignancy. Neoplasia 2001;3: 371-384.
96. Mueller BM, Reisfeld RA, Edgington TS, Ruf W: Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci USA 1992;89:11832-11836.
97. Seto S, Onodera H, Kaido T, Yoshikawa A, Ishigami S, Arii S, Imamura M: Tissue factor expression in human colorectal carcinoma: correlation with hepatic metastasis and impact on prognosis. Cancer 2000;88: 295-301.
98. Shigemori C, Wada H, Matsumoto K, Shiku H, Nakamura S , Suzuki H: Tissue factor expression and metastatic potential of colorec-tal cancer. Thromb Haemost 1998;80:894-898.
99. Nakasaki T, Wada H, Shigemori C, Miki C, Gabazza EC, Nobori T, Nakamura S, Shiku H: Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in colorectal cancer. Am J Hematol 2002;69:247-254.
100. Zhang J, Ding J, Zhang X, Shao X, Hao Z: Regulation of vascular endothelial growth factor production and angiogenesis by tissue factor in SGC-7901 gastric cancer cells. Cancer Biol Ther 2005;4:769-772.
101. Wang X, Gjernes E, Prydz H: Factor VIIa induces tissue factor-dependent up-regula-tion of interleukin-8 in a human keratinocyte line. J Biol Chem 2002;277:23620-23626.
102. Hirashima M, Ogawa M, Nishikawa S, Matsumura K, Kawasaki K, Shibuya M, Nishikawa S: A chemically defined culture of VEGFR2+ cells derived from embryonic stem cells reveals the role of VEGFR1 in tuning the threshold for VEGF in developing endothelial cel ls. Blood 2003;101:2261-2267.
103. Versteeg HH, Schaffner F, Kerver M, Pe-tersen HH, Ahamed J, Felding-Habermann B, Takada Y, Mueller BM, Ruf W: Inhibition of tissue factor signaling suppresses tumor growth. Blood 2008;111:190-199.
104. Zhang Y, Deng Y, Luther T, Muller M, Ziegler R, Waldherr R, Stern DM, Nawroth PP: Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 1994;94: 1320-1327.
105. Ngo CV, Picha K, McCabe F, Millar H, Tawadros R, Tam SH, Nakada MT, Anderson GM: CNTO 859, a humanized anti-tissue factor monoclonal antibody, is a potent inhibitor of breast cancer metastasis and tumor growth in xenograft models. Int J Cancer 2007;120:1261-1267.
106. Milsom C, Anderson GM, Weitz JI, Rak J: Elevated tissue factor procoagulant activity in CD133-positive cancer cells. J Thromb Haemost 2007;5:2550-2552.
107. Toomey JR, Kratzer KE, Lasky NM, Broze GJ Jr: Effect of tissue factor deficiency on mouse and tumor development. Proc Natl Acad Sci USA 1997;94:6922-6926.
108. Palumbo JS, Barney KA, Blevins EA, Shaw MA, Flick MJ, Kombrinck KW, Talmage KE, Souri M, Ichinose A, Degen JL: Factor XIII transglutaminase supports hematogenous tumor cell metastasis through a mechanism dependent on natural killer cell function. J Thromb Haemost 2008;6:812-819.
109. Mechtcheriakova D, Schabbauer G, Lucer-na M, Clauss M, de Martin R, Binder BR Hofer E: Specificity, diversity, and convergence in VEGF and TNF-αsignaling events leading to tissue factor up-regulation via EGR-1 in endothelial cells. FASEB J 2001;15:230-242.
110. Ollivier V, Bentolila S, Chabbat J, Hakim J, de Prost D: Tissue factor-dependent vascular endothelial growth factor production by human fibroblasts in response to activated factor VII. Blood 1998;91:2698-2703.
111. Bombeli T, Karsan A, Tait JF, Harlan JM: Apoptotic vascular endothelial cells become procoagulant. Blood 1997;89:2429-2442.
112. Lwaleed BA, Francis JL, Chisholm M: Monocyte tissue factor levels in cancer patients. Saudi Med J 2000;21:722-729.
113. Verheul HM, Jorna AS, Hoekman K, Broxterman HJ, Gebbink MF, Pinedo HM: Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets. Blood 2000;96:4216-4221.
114. Rong Y, Hu F, Huang R Mackman N, Horowitz JM, Jensen RL, Durden DL, Van Meir EG, Brat DJ: Early growth response gene-1 regulates hypoxia-induced expression of tissue factor in glioblastoma multiforme through hypoxia-inducible factor-1-independent mechanisms. Cancer Res 2006;66:7067-7074.
115. Milsom C, Rak J: Regulation of tissue factor and angiogenesis-related genes by changes in cell shape. Biochem Biophys Res Com-mun 2005;337:1267-1275.
116. Kato S, Pinto M, Carvajal A, Espinoza N, Monso C, Bravo L, Villalon M, Cuello M, Quest AF, Suenaga A, Brosens JJ, Owen GI: Tissue factor is regulated by epidermal growth factor in normal and malignant human endometrial epithelial cells. Thromb Haemost 2005;94:444-453.
117. Kato S, Pinto M, Carvajal A, Espinoza N, Monso C, Sadarangani A, Villalon M, Brosens JJ, White JO, Richer JK, Horwitz KB, Owen GI: Progesterone increases tissue factor gene expression, procoagulant activity, and invasion in the breast cancer cell line ZR-75-1. J Clin Endocrinol Metab 2005;90: 1181-1188.
118. Rong Y, Durden DL, Van Meir EG, Brat DJ: 'Pseudopalisading' necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J Neuropathol Exp Neurol 2006;65:529-539.
119. Cochran DM, Fukumura D, Ancukiewicz M, Carmeliet P, Jain RK: Evolution of oxygen and glucose concentration profiles in a tissue-mimetic culture system of embryonic stem cells. Ann Biomed Eng 2006;34: 1247-1258.
120. Rak J, Klement G: Impact of oncogenes and tumor suppressor genes on deregulation of hemostasis and angiogenesis in cancer. Cancer Metastasis Rev 2000;19:93-96.
121. Yu JL, May L, Klement P, Weitz JI, Rak J: Oncogenes as regulators of tissue factor expression in cancer: implications for tumor angiogenesis and anti-cancer therapy. Semin Thromb Hemost 2004;30:21-30.
122. Rak J, Milsom C, May L, Klement P, Yu J: Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy. Semin Thromb Hemost 2006;32:54-70.
123. Al-Nedawi K, Meehan B, Micallef J, Lhotak V, May L, Guha A, Rak J: Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol 2008;10:619-624.
124. Klement P, Rak J: Emerging anticoagulants: mechanism of action and future potential. Vnitr Lek 20 06;52(suppl 1):119-122.
125. Izumi H, Takahashi C, Oh J, Noda M: Tissue factor pathway inhibitor-2 suppresses the production of active matrix metallo-proteinase-2 and is down-regulated in cells harboring activated ras oncogenes. FEBS Lett 2000;481:31-36.
126. Koizume S, Jin MS, Miyagi E, Hirahara F, Nakamura Y, Piao JH, Asai A, Yoshida A, Tsuchiya E, Ruf W, Miyagi Y: Activation of cancer cell migration and invasion by ectopic synthesis of coagulation factor VII. Cancer Res 2006;66:9453-9460.
127. Schulze EB, Hedley BD, Goodale D, Postenka CO, Al Katib W, Tuck AB, Chambers AF, Allan AL: The thrombin inhibitor Argat-roban reduces breast cancer malignancy and metastasis via osteopontin-dependent and osteopontin-independent mechanisms. Breast Cancer Res Treat 2008;112:243-254.
128. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusima-no MD, Dirks PB: Identification of human brain tumour initiating cells. Nature 2004;432:396-401.
129. Ruf W, Mueller BM: Tissue factor signaling. Thromb Haemost 1999;82: 17 5-18 2 .
130. Palumbo JS, Potter JM, Kaplan LS, Talmage K, Jackson DG, Degen JL: Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res 2002;62:6966-6972.
131. Francis JL, Amirkhosravi A: Effect of antihemostatic agents on experimental tumor dissemination. Semin Thromb Hemost 2002;28:29-38.
132. Ruf W, Mueller BM: Tissue factor in cancer angiogenesis and metastasis. Curr Opin Hematol 1996;3:379-384.
133. Hembrough TA, Swartz GM, Papathanassiu A, Vlasuk GP, Rote WE, Green SJ, Pribluda VS: Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a non-hemostatic mechanism. Cancer Res 2003;63:2997-3000.
134. Levine MN, Gent M, Hirsh J, Arnold A, Goodyear MD, Hryniuk W, De Pauw S: The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 1988;318:404-407.
135. Verheul HM, Pinedo HM: Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007;7:475-485.
136. Kaushal V, Mukunyadzi P, Siegel ER, Dennis RA, Johnson DE, Kohli M: Expression of t issue factor in prostate cancer cor relates with malignant phenotype. Appl Immuno-histochem Mol Morphol 2008;16:1-6.
137. Hembrough TA, Ruiz JF, Swerdlow BM, Swartz GM, Hammers HJ, Zhang L, Plum SM, Williams MS, Strickland DK, Pribluda VS: Identification and characterization of a very low density lipoprotein receptor binding peptide from tissue factor pathway inhibitor that has antitumor and antiangiogenic activity. Blood 2004;103:3374-3380.
138. Bromberg ME, Konigsberg WH, Madison JF, Pawashe A, Garen A: Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. Proc Natl Acad Sci USA 1995;92:8205-8209.
139. Wang X, Wang M, Amarzguioui M, Liu F, Fodstad O, Prydz H: Downregulation of tissue factor by RNA interference in human melanoma LOX-L cells reduces pulmonary metastasis in nude mice. Int J Cancer 2004;112:994-1002.
140. Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, Hu Z, Barney KA, Degen JL: Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms. Blood 2007;110:133-141.
141. Ngo CV, Manning CA, McCabe F, Millar H, Nakada MT, Anderson GM: Combination antibody therapy targeting both xenograft-and host-derived tissue factor leads to potent tumor inhibition. Proc Am Assoc Cancer Res 2005;46 (abstr 548).
142. Talmadge JE, Zbar B: Clonality of pulmonary metastases from the bladder 6 subline of the B16 melanoma studied by Southern hybridization. J Natl Cancer Inst 1987;78: 315-320.
143. Jones TD, Carr MD, Elbe JN, Wang M, Lopez-Beltran E, Cheng L: Clonal origin of lymph node metastases in bladder carcinoma. Cancer 2005;104:1901-1910.
144. Rak J, Milsom C, May L, Klement P, Yu J: Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy. Semin Thromb Hemost 2006;32:54-70.
145. Nierodzik M, Karpatkin S: Hypercoagulability preceding cancer. Does hypercoagulability awaken dormant tumor cells in the host? J Thromb Haemost 2005;3:577-580.
146. Pakneshan P, Szyf M, Rabbani SA: Methylation and inhibition of expression of uPA by the RAS oncogene: divergence of growth control and invasion in breast cancer cells. Carcinogenesis 2005;26:557-564.
147. Zhu X, Giordano T, Yu QS, Holloway HW, Perry TA, Lahiri DK, Brossi A, Greig NH: Thiothalidomides: novel isosteric analogues of thalidomide with enhanced TNF-αinhibitory activity. J Med Chem 2003;46: 5222-5229.
148. Folkman J: Angiogenesis and proteins of the hemostatic system. J Thromb Haemost 2003;1:1681-1682.
149. Browder T, Folkman J, Pirie-Shepherd S: The hemostatic system as a regulator of angiogenesis. J Biol Chem 2000;275:1521-1524.
150. Verheul HM, Pinedo HM: Tumor growth: a putative role for platelets? Oncologist 1998;3:ii.
151. Contrino J, Hair G, Kreutzer DL, Rickles FR: In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med 1996;2:209-215.
152. Gilbertson RJ, Rich JN: Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer 2007;7:733-736.
153. Rich JN: Cancer stem cells in radiation resistance. Cancer Res 2007;67:8980-8984.
154. Folkman J: Fundamental concepts of the angiogenic process. Curr Mol Med 2003;3: 643-651.
155. Jain RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
156. Hurwitz H, Fehrenbacher L, Cartwright T, Hainsworth J, Heim W, Berlin J, Griffing S, Novotny W, Holmgren E, Kabbinavar F: Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Abstracts ASCO, 2003.
157. Ferrara N: Vascular endothelial growth factor as a target for anticancer therapy Oncologist 2004;9(suppl 1):2-10.
158. Hurwitz H: Integrating the anti-VEGF-A humanized monoclonal antibody bevaci-zumab with chemotherapy in advanced colorectal cancer. Clin Colorectal Cancer 2004;4(suppl 2):S62-S68.
159. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550.
160. Faivre S, Demetri G, Sargent W, Raymond E: Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007;6:734-745.
161. Kakkar AK, Levine MN, Kadziola Z, Lemoine NR, Low V, Patel HK, Rustin G, Thomas M, Quigley M, Williamson RC: Low-molecular-weight heparin, therapy with dalteparin, and survival in advanced cancer: the Fragmin Advanced Malignancy Outcome Study (FAMOUS). J Clin Oncol 2004;22:1944-1948.
162. Lee AY, Rickles FR, Julian JA, Gent M, Baker RI, Bowden C, Kakkar AK, Prins M, Levine MN: Randomized comparison of low-molecular-weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005;23:2123-2129.
163. Klerk CP, Smorenburg SM, Otten HM, Lensing AW, Prins MH, Piovella F, Prandoni P, Bos MM, Richel DJ, van Tienhoven G, Buller HR: The effect of low-molecular-weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005;23:2130-2135.
164. Altinbas M, Coskun HS, Er O, Ozkan M, Eser B, Unal A, Cetin M, Soyuer S:
165. Mueller BM, Ruf W: Requirement for binding of catalytically active factor VIIa in tissue factor-dependent experimental metastasis. J Clin Invest 1998;101:1372-1378.
166. Kessler T, Bieker R, Padro T, Schwoppe C, Persigehl T, Bremer C, Kreuter M, Berdel WE, Mesters RM: Inhibition of tumor growth by RGD peptide-directed delivery of truncated tissue factor to the tumor vasculature. Clin Cancer Res 2005;11:6317-6324.
167. Amarzguioui M, Peng Q, Wiiger MT, Vasovic V, Babaie E, Holen T, Nesland JM, Prydz H: Ex vivo and in vivo delivery of anti-tissue factor short interfering RNA inhibits mouse pulmonary metastasis of B16 melanoma cells. Clin Cancer Res 2006;12:4055-4061.
168. Viloria-Petit A, Miquerol L, Yu JL, Gertsenstein M, Sheehan C, May L, Henkin J, Lobe C, Nagy A, Kerbel RS, Rak J: Contrasting effects of VEGF gene disruption in embryonic stem cell-derived versus oncogene-in-duced tumors. EMBO J 2003;22:4091-4102.
169. Yu JL, Coomber BL, Kerbel RS: A paradigm for therapy-induced microenvironmental changes in solid tumors leading to drug resistance. Differentiation 2002;70:599-609.
170. Wang JG, Mahmud SA, Thompson JA, Geng JG, Key NS, Slungaard A: The principal eosinophil peroxidase product, HOSCN, is a uniquely potent phagocyte oxidant inducer of endothelial cell tissue factor activity: a potential mechanism for thrombosis in eosinophilic inflammatory states. Blood 2006;107:558-565.
171. Szotowski B, Antoniak S, Poller W, Schultheiss HP, Rauch U: Procoagulant-soluble tissue factor is released from endothelial cells in response to inflammatory cytokines. Circ Res 2005;96:1233-1239.
172. Speiser W, Kapiotis S, Kopp CW, Simonitsch I, Jilma B, Jansen B, Exner M, Chott A: Effect of intradermal tumor necrosis factor-α-induced inflammation on coagulation factors in dermal vessel endothelium. An in vivo study of human skin biopsies. Thromb Haemost 2001;85:362-367.
173. Camera M, Giesen PL, Fallon J, Aufiero BM, Taubman M, Tremoli E, Nemerson Y Cooperation between VEGF and TNF-alpha;is necessary for exposure of active tissue factor on the surface of human endothelial cells. Arterioscler Thromb Vasc Biol 1999;19:531-537.
174. Clauss M, Grell M, Fangmann C, Fiers W, Scheurich P, Risau W: Synergistic induction of endothelial tissue factor by tumor necrosis factor and vascular endothelial growth factor: functional analysis of the tumor necrosis factor receptors. FEBS Lett 1996;390:334-338.
175. Mackman N: Regulation of tissue factor gene expression in human monocytic and endothelial cells. Haemostasis 1996;26 (suppl 1):17-19.
176. Bierhaus A, Zhang Y, Deng Y, Mackman N, Quehenberger P, Haase M, Luther T, Muller M, Bohrer H, Greten J: Mechanism of the tumor necrosis factor-α-mediated induction of endothelial tissue factor. J Biol Chem 1995;270:26419-26432.
177. Parry GC, Mackman N: Transcriptional regulation of tissue factor expression in human endothelial cells. Arterioscler Thromb Vasc Biol 1995;15: 612-621.
178. Moll T, Czyz M, Holzmuller H, Hofer-Warbinek R, Wagner E, Winkler H, Bach FH, Hofer E: Regulation of the tissue factor promoter in endothelial cells. Binding of NF-κB-, AP-1-, and Sp1-like transcription factors. J Biol Chem 1995;270: 3849-3857.
179. Nawroth PP, Stern DM: Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986;163: 740-745.
180. Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS, Gimbrone MA Jr: Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin-1. Proc Natl Acad Sci USA 1986;83:4533-4537.
181. Guha M, O'Connell MA, Pawlinski R, Hollis A, McGovern P, Yan SF, Stern D, Mackman N: Lipopolysaccharide activation of the MEK-ERK1/2 pathway in human monocytic cells mediates tissue factor and tumor necrosis factor- αexpression by inducing Elk-1 phosphorylation and Egr-1 expression. Blood 2001;98: 1429-1439.
182. Butenas S, Bouchard BA, Brummel-Ziedins KE, Parhami-Seren B, Mann KG: Tissue factor activity in whole blood. Blood 2005;105:2764-2770.
183. Van der Logt CP, Dirven RJ, Reitsma PH, Bertina RM: Expression of tissue factor and tissue factor pathway inhibitor in monocytes in response to bacterial lipopolysaccharide and phorbol ester. Blood Coagul Fibrinolysis 1994;5:211-220.
184. Conkling PR, Greenberg CS, Weinberg JB: Tumor necrosis factor induces tissue factor-like activity in human leukemia cell line U937 and peripheral blood monocytes. Blood 1988;72: 128-133.
185. Grignani G, Maiolo A: Cytokines and hemostasis. Haematologica 2000;85:967-972.
186. Schecter AD, Giesen PL, Taby O, Rosenfield CL, Rossikhina M, Fyfe BS, Kohtz DS, Fallon JT, Nemerson Y, Taubman MB: Tissue factor expression in human arterial smooth muscle cells. TF is present in three cellular pools after growth factor stimulation. J Clin Invest 1997;100:2276-2285.
187. Mechtcheriakova D, Wlachos A, Holzmuller H, Binder BR, Hofer E: Vascular endothelial cell growth factor-induced tissue factor expression in endothelial cells is mediated by EGR-1. Blood 1999;93:3811-3823.
188. Zucker S, Mirza H, Conner CE, Lorenz AF, Drews MH, Bahou WF, Jesty J: Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation. Int J Cancer 1998;75:780-786.
189. Clauss M, Weich H, Breier G, Knies U, Rockl W, Waltenberger J, Risau W: The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem 1996;271:17629-17634.
190. Edgington TS, Mackman N, Brand K, Ruf W: The structural biology of expression and function of tissue factor. Thromb Haemost 1991;66:67-79.
191. Xuereb JM, Sie P, Boneu B, Constans J: Up-regulation of tissue factor expression by platelet-derived growth factor in human vascular smooth muscle cells in culture-role of mitogen-activated protein kinase and effects of intracellular cyclic AMP. Thromb Haemost 1997;78:1520-1526.
192. Mackman N: Regulation of the tissue factor gene. FASEB J 1995;9:883-889.
193. Cui MZ, Parry GC, Edgington TS, Mackman N: Regulation of tissue factor gene expression in epithelial cells. Induction by serum and phorbol 12-myristate 13-acetate. Arterioscler Thromb 1994;14:807-814.
194. Faucette KJ, Parker CJ, McCluskey T, Bernshaw NJ, Rodgers GM: Induction of tissue factor activity in endothelial cells and monocytes by a modified form of albumin present in normal human plasma. Blood 1992;79:2888-2895.
195. Ollivier V, Hammal S, Ameziane N, Labro MT, de Prost D: Modulation of tissue factor expression by rapamycin and FK-506 in lipopolysaccharide- stimulated human mononuclear cells and serum-stimulated aortic smooth muscle cells. Thromb Haemost 2005;94:46-52.
196. Xuereb JM, Sie P, Boneu B, Constans J: Inhibition of tissue factor synthesis by disruption of ERK kinases and PKC signaling pathways in human vascular SMCs. Thromb Haemost 2000;84:129-136.
197. Felts SJ, Stoflet ES, Eggers CT, Getz MJ: Tissue factor gene transcription in serum-stimulated fibroblasts is mediated by recruitment of c-Fos into specific AP-1 DNA-binding complexes. Biochemistry 1995;34:12355-12362.
198. Bloem LJ, Chen L, Konigsberg WH, Bach R: Serum stimulation of quiescent human fi-broblasts induces the synthesis of tissue factor m R NA fol lowed by t he appea r a nce of tissue factor antigen and procoagulant activity. J Cell Physiol 1989;139:418-423.
199. Yan SF, Lu J, Xu L, Zou YS, Tongers J, Kisiel W, Mackman N, Pinsky DJ, Stern DM: Pulmonary expression of early growth response-1: biphasic time course and effect of oxygen concentration. J Appl Physiol 2000;88:2303-2309.
200. Yan SF, Zou YS, Gao Y, Zhai C, Mackman N, Lee SL, Milbrandt J, Pinsky D, Kisiel W, Stern D: Tissue factor transcription driven by Egr-1 is a critical mechanism of murine pulmonary fibrin deposition in hypoxia. Proc Natl Acad Sci USA 1998;95:8298-8303.
201. BelAiba RS, Djordjevic T, Bonello S, Artunc F, Lang F, Hess J, Gorlach A: The serum- and glucocorticoid-inducible kinase Sgk-1 is involved in pulmonary vascular remodeling: role in redox-sensitive regulation of tissue factor by thrombin. Circ Res 2006;98:828-836.
202. Gorlach A, BelAiba RS, Hess J, Kietzmann T: Thrombin activates the p21-activated kinase in pulmonary artery smooth muscle cells. Role in tissue factor expression. Thromb Haemost 2005;93:1168-1175.
203. Djordjevic T, Hess J, Herkert O, Gorlach A, BelAiba RS: Rac regulates thrombin-induced tissue factor expression in pulmonary artery smooth muscle cells involving the nuclear factor-κB pathway. Antioxid Redox Signal 2004;6:713-720.
204. Zacharski LR, Wojtukiewicz MZ, Costantini V Ornstein DL, Memoli VA: Pathways of coagulation/fibrinolysis activation in malignancy. Semin Thromb Hemost 1992;18:104-116.
205. Bavendiek U, Libby P, Kilbride M, Reynolds R, Mackman N, Schonbeck U: Induction of tissue factor expression in human endothelial cells by CD40 ligand is mediated via activator protein 1, nuclear factor-κB, and Egr-1. J Biol Chem 2002;277:25032-25039.
206. Schonbeck U, Mach F, Sukhova GK, Herman M, Graber P, Kehry MR, Libby P: CD40 ligation induces tissue factor expression in human vascular smooth muscle cells. Am J Pathol 2000;156:7-14.
207. 2+ mobilization and protein kinase C activation. J Clin Invest 1993;91: 547-552.
208. Essayagh S, Xuereb JM, Terrisse AD, Tellier-Cirioni L, Pipy B, Sie P: Microparticles from apoptotic monocytes induce transient platelet recruitment and tissue factor expression by cultured human vascular endothelial cells via a redox-sensitive mechanism. Thromb Haemost 2007;98:831-837.
209. Sugiyama S, Kugiyama K, Aikawa M, Nakamura S, Ogawa H, Libby P: Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression: involvement of myeloperoxidase-mediated oxidant in plaque erosion and thrombogenesis. Arterioscler Thromb Vasc Biol 2004;24:1309-1314.
210. Goldin-Lang P, Niebergall F, Antoniak S, Szotowski B, Rosenthal P, Pels K, Schult-heiss HP, Rauch U: Ionizing radiation induces upregulation of cellular procoagulability and tissue factor expression in human peripheral blood mononuclear cells. Thromb Res 2007;120:857-864.
211. Henriksson CE, Klingenberg O, Ovstebo R, Joo GB, Westvik AB, Kierulf P: Discrepancy between tissue factor activity and tissue factor expression in endotoxin-induced monocytes is associated with apoptosis and necrosis. Thromb Haemost 2005;94:1236-1244.
212. Eisenreich A, Celebi O, Goldin-Lang P, Schultheiss HP, Rauch U: Upregulation of tissue factor expression and thrombogenic activity in human aortic smooth muscle cells by irradiation, rapamycin and pacli-taxel. Int Immunopharmacol 2008;8:307-311.
213. Zhu J, Guo WM, Yao YY, Zhao WL, Pan L, Cai X, Ju B, Sun GL, Wang HL, Chen SJ, Chen GQ, Caen J, Chen Z, Wang ZY: Tissue factors on acute promyelocytic leukemia and endothelial cells are differently regulated by retinoic acid, arsenic trioxide and chemotherapeutic agents. Leukemia 1999;13:1062-1070.
214. Hair GA, Padula S, Zeff R, Schmeizl M, Contrino J, Kreutzer DL, de MP, Boyd AW, Stanley I, Burgess AW, Rickles FR: Tissue factor expression in human leukemic cells. Leuk Res 1996;20:1-11.
215. Gordon JN, Trebble TM, Ellis RD, Duncan HD, Johns T, Goggin PM: Thalidomide in the treatment of cancer cachexia: a randomised placebo-controlled trial. Gut 2005;54:540-545.
216. Kuenen BC: Analysis of prothrombotic mechanisms and endothelial perturbation during treatment with angiogenesis inhibitors. Pathophysiol Haemost Thromb 2003;33(suppl 1):13-14.
217. Murray JC, Clauss M, Denekamp J, Stern D: Selective induction of endothelial cell tissue factor in the presence of a tumour-derived mediator: a potential mechanism of flavone acetic acid action in tumour vasculature. Int J Cancer 1991;49:254-259.
218. Lesnik P, Rouis M, Skarlatos S, Kruth HS, Chapman MJ: Uptake of exogenous free cholesterol induces upregulation of tissue factor expression in human monocyte-derived macrophages. Proc Natl Acad Sci USA 1992;89:10370-10374.
219. Llorente-Cortes V, Otero-Vinas M, Camino-Lopez S, Llampayas O, Badimon L: Aggregated low-density lipoprotein uptake induces membrane tissue factor procoagulant activity and microparticle release in human vascular smooth muscle cells. Circulation 2004;110:452-459.
220. Vega-Ostertag M, Casper K, Swerlick R, Ferrara D, Harris EN, Pierangeli SS: Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum 2005;52:1545-1554.
221. Branch DW, Rodgers GM: Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: a possible mechanism of thrombosis. Am J Obstet Gy necol 1993;168:206-210.
222. Hasselaar P, Derksen RH, Oosting JD, Blokzijl L, De Groot PG: Synergistic effect of low doses of tumor necrosis factor and sera from patients with systemic lupus erythematosus on the expression of procoagulant activity by cultured endothelial cells. Thromb Haemost 1989;62:654-660.
223. Tannenbaum SH, Finko R, Cines DB: Antibody and immune complexes induce tissue factor production by human endothelial cells. J Immunol 1986;137:1532-1537.
224. Lopez-Pedrera C, Buendia P, Barbarroja N, Siendones E, Velasco F, Cuadrado MJ: Antiphospholipid-mediated thrombosis: interplay between anticardiolipin antibodies and vascular cells. Clin Appl Thromb He-most 2006;12:41-45.
225. Dupuy E, Hainaud P, Villemain A, Bodevin-Phedre E, Brouland JP, Briand P, Tobelem G: Tumoral angiogenesis and tissue factor expression during hepatocellular carcinoma progression in a transgenic mouse model. J Hepatol 2003;38:793-802.
226. Vrana JA, Stang MT, Grande JP, Getz MJ: Expression of tissue factor in tumor stroma correlates with progression to invasive human breast cancer: paracrine regulation by carcinoma cell-derived members of the transforming growth factor-βfamily. Cancer Res 1996;56:5063-5070.
227. Callander NS, Varki N, Rao LV: Immuno-histochemical identification of tissue factor in solid tumors. Cancer 1992;70:1194-1201.
228. Clauss M, Murray JC, Vianna M, de Waal R, Thurston G, Nawroth P, Gerlach H, Bach R, Familletti PC, Stern D: A polypeptide factor produced by fibrosarcoma cells that induces endothelial tissue factor and enhances the procoagulant response to tumor necrosis factor/cachectin. J Biol Chem 1990;265:7078-7083.
229. Osterud B: Tissue factor expression by monocytes: regulation and pathophysiological roles. Blood Coagul Fibrinolysis 1998;9(suppl 1):S9-S14.
230. Decousus H, Moulin N, Quenet S, Bost V, Rivron-Guillot K, Laporte S, Mismetti P: Thrombophilia and risk of venous thrombosis in patients with cancer. Thromb Res 2007;120(suppl2):S51-S61.
231. Lee AY, Levine MN: The thrombophilic state induced by therapeutic agents in the cancer patient. Semin Thromb Hemost 1999;25:137-145.
232. Amirkhosravi M, Francis JL: Coagulation activation by MC28 fibrosarcoma cells facilitates lung tumor formation. Thromb Haemost 1995;73:59-65.
233. Francis PA, Rigas JR, Kris MG, Pisters KM, Orazem JP, Woolley KJ, Heelan RT: Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol 1994;12:1232-1237.
234. Rickles FR, Levine M, Edwards RL: Hemostatic alterations in cancer patients. Cancer Metastasis Rev 1992;11:237-248.
235. Rickles FR, Edwards RL: Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 1983;62:14-31.
236. Rickles FR, Shoji M, Abe K: The role of the hemostatic system in tumor growth, metastasis, and angiogenesis: tissue factor is a bi-functional molecule capable of inducing both fibrin deposition and angiogenesis in cancer. Int J Hematol 2001;73:145-150.
237. Abdulkadir SA, Carvalhal GF, Kaleem Z, Kisiel W, Humphrey PA, Catalona WJ, Milbrandt J: Tissue factor expression and an-giogenesis in human prostate carcinoma. Hum Pathol 2000;31:443-447.
238. Shoji M, Hancock WW, Abe K, Micko C, Casper KA, Baine RM, Wilcox JN, Danave I, Dillehay DL, Matthews E, Contrino J, Morrissey JH, Gordon S, Edgington TS, Kudryk B, Kreutzer DL, Rickles FR: Activation of coagulation and angiogenesis in cancer: immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer. Am J Pathol 1998;152:399-411.
239. Folkman J: Tumor angiogenesis and tissue factor. Nat Med 1996;2:167-168.
240. Morris DR, Ding Y, Ricks TK, Gullapalli A, Wolfe BL, Trejo J: Protease-activated receptor-2 is essential for factor VIIa and Xa-induced signaling, migration, and invasion of breast cancer cells. Cancer Res 2006;66: 307-314.
241. Jiang X, Bailly MA, Panetti TS, Cappello M, Konigsberg WH, Bromberg ME: Formation of tissue factor-factor VIIa-factor Xa complex promotes cellular signaling and migration of human breast cancer cells. J Thromb Haemost 2004;2:93-101.
242. Hjortoe GM, Petersen LC, Albrektsen T, Sorensen BB, Norby PL, Mandal SK, Pen-durthi UR, Rao LV: Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration. Blood 2004;103:3029-3037.
243. Di Raimondo F, Azzaro MP, Palumbo G, Bagnato S, Giustolisi G, Floridia P, Sortino G, Giustolisi R: Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood. Haematolo-gica 2000;85:800-805.
244. Palumbo JS, Degen JL: Hemostatic factors in tumor biology. J Pediatr Hematol Oncol 2000;22:281-287.
245. Wojtukiewicz MZ, Tang DG, Ciarelli JJ, Nelson KK, Walz DA, Diglio CA, Mammen EF, Honn KV: Thrombin increases the metastatic potential of tumor cells. Int J Cancer 1993;54:793-806.
246. Nierodzik ML, Plotkin A, Kajumo F, Karpatkin S: Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo. J Clin Invest 1991;87:229-236.
247. Langer F, Amirkhosravi A, Loges S, Meyer T, Eifrig B, Hossfeld DK, Fiedler W, Francis JL: An in vitro study on the mechanisms of coagulation activation in acute myelogenous leukemia: role of tissue factor regulation by cytotoxic drugs and GM-CSF. Thromb Haemost 2004;92:1136-1146.
248. Versteeg HH, Ruf W: Tissue factor coagulant function is enhanced by protein-disulfide isomerase independent of oxidore-ductase activity. J Biol Chem 2007;282: 25416-25424.
249. Versteeg HH, Ruf W: Emerging insights in tissue factor-dependent signaling events. Semin Thromb Hemost 2006;32:24-32.
250. Hamilton JR, Cornelissen I, Coughlin SR: Impaired hemostasis and protection against thrombosis in protease-activated receptor 4-deficient mice is due to lack of thrombin signaling in platelets. J Thromb Haemost 2004;2:1429-1435.
251. Jiang X, Guo YL, Bromberg ME: Formation of tissue factor-factor VIIa-factor Xa complex prevents apoptosis in human breast cancer cells. Thromb Haemost 2006;96: 196-201.
252. Volm M, Koomagi R, Efferth T, Mattern J: Protein expression profiles of non-small cell lung carcinomas: correlation with histologica l subtype. Anticancer Res 2002;22: 2321-2324.
253. Lwaleed BA: The clinical value of measuring tissue factor activity in patients with cancer. Med Hy potheses 2002;58:521-522.
254. Buller HR, van Doormaal FF, van Sluis GL, Kamphuisen PW: Cancer and thrombosis: from molecular mechanisms to clinical presentations. J Thromb Haemost 2007;5(suppl 1):246-254.
255. Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, Bergs-land E, Ngai J, Holmgren E, Wang J, Hurwitz H: Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007;99:1232-1239.
256. Niers TM, Klerk CP, Dinisio M, van Noorden CJ, Buller HR, Reitsma PH, Richel DJ: Mechanisms of heparin induced anti-cancer activity in experimental cancer models. Crit Rev Oncol Hematol 2007;61:195-207.
257. Mousa S, Mousa SA: Cellular and molecular mechanisms of nicotine's pro-angiogen-esis activity and its potential impact on cancer. J Cell Biochem 2006;97:1370-1378.
258. Lee AY, Rickles FR, Julian JA, Gent M, Baker RI, Bowden C, Kakkar AK, Prins M, Levine MN: Randomized comparison of low-molecular-weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005;23:2123-2129.
259. Kakkar AK: Low-molecular-weight heparin and survival in patients with malignant disease. Cancer Control 2005;12(suppl 1): 22-30.
260. Kakkar AK: Low- and ultra-low-molecular-weight heparins. Best Pract Res Clin Haematol 2004;17:77-87.
261. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M: Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-153.
262. Amirkhosravi A, Mousa SA, Amaya M, Francis JL: Antimetastatic effect of tinza-parin, a low-molecular-weight heparin. J Thromb Haemost 2003;1:1972-1976.
263. Rickles FR, Patierno SR, Fernandez PM: Targeting the endothelium in cancer- the importance of the interaction of hemostatic mechanisms and the vascular wall for tumor growth and angiogenesis. Pathophysiol Haemost Thromb 2003;33(suppl 1):1-4.
264. Kakkar AK, Chinswangwatanakul V, Teb-butt S, Lemoine NR, Williamson RC: A characterization of the coagulant and fibrinolytic profile of human pancreatic carcinoma cells. Haemostasis 1998;28:1-6.
265. Kakkar AK, Williamson RC: Prevention of venous thromboembolism in cancer using low-molecular-weight heparins. Haemostasis 1997;27(suppl 1):32-37.
266. Levine M: Treatment of thrombotic disorders in cancer patients. Haemostasis 1997;27(suppl 1):38-43.
267. Francis JL, Carty N, Amirkhosravi M, Loizidou M, Cooper A, Taylor I: The effect of warfarin and factor VII on tissue procoag-ulant activity and pulmonary seeding. Br J Cancer 1992;65:329-334.
268. Ruf W, Edgington TS: An anti-tissue factor monoclonal antibody which inhibits TFVI-Ia complex is a potent anticoagulant in plasma. Thromb Haemost 1991;66:529-533.
269. McCulloch P, George WD: Promotion of metastasis by a specific complex of coagulation factors may be independent of fibrin formation. Br J Cancer 1988;58:158-162.
270. Zacharski LR, Henderson WG, Rickles FR, Forman WB, Cornell CJ Jr, Forcier RJ, Edwards RL, Headley E, Kim SH, O'Donnell JF: Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study No 75. Cancer 1984;53:2046-2052.
271. Folkman J, Langer R, Linhardt RJ, Haudenschild C, Taylor S: Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science 1983;221:719-725.
272. Sanz MA, Martin G, Rayon C, Esteve J, Gonzalez M, Diaz-Mediavilla J, Bolufer P, Barragan E, Terol MJ, Gonzalez JD, Co-lomer D, Chillon C, Rivas C, Gomez T, Ribera JM, Bornstein R, Roman J, Calasanz MJ, Arias J, Alvarez C, Ramos F, Deben G: A modified AIDA protocol with anthracy-cline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARα-positive acute promyelocytic leukemia. PETHEMA group. Blood 1999;94:3015-3021.
273. Wang J, Zheng H, Ou X, Albertson CM, Fink LM, Herbert JM, Hauer-Jensen M: Hirudin ameliorates intestinal radiation toxicity in the rat: support for thrombin inhibition as strategy to minimize side-effects after radiation therapy and as countermea-sure against radiation exposure. J Thromb Haemost 2004;2:2027-2035.
274. Amirkhosravi A, Meyer T, Chang JY, Amaya M, Siddiqui F, Desai H, Francis JL: Tissue factor pathway inhibitor reduces experimental lung metastasis of B16 melanoma. Thromb Haemost 2002;87:930-936.
275. Forster Y, Schwenzer B: Inhibition of TF gene expression by antisense oligonucleotides in different cancer cell lines. J Exp Ther Oncol 2004;4:281-289.
276. Palumbo JS, Kombrinck KW, Drew AF, Grimes TS, Kiser JH, Degen JL, Bugge TH: Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 2000;96:3302-3309.
277. Wang D, DuBois RN: Inflammatory mediators and nuclear receptor signaling in colorectal cancer. Cell Cycle 2007;6:682-685.
278. Yu J, May L, Milsom C, Anderson GM, Weitz JI, Luyendyk JP, Broze G, Mackman N, Rak J: Contribution of host-derived tissue factor to tumor neovascularization. Arterioscler Thromb Vasc Biol 2008;28: 1975-1981.
279. Milsom CC, Yu JL, Mackman N, Micallef J, Anderson GM, Guha A, Rak J: Tissue factor regulation by epidermal growth factor receptor and epithelial-to-mesenchymal transitions: Effect on tumor initiation and angiogenesis. Cancer Res 2008, in press.